Wigglyick
Posted - 10 hours ago
@IsabellaDC @Cash4freedom @net0trader @MaverikIT @Im_not_Mr_Lebowski @DonCorleone77 @RonIsWrong $RZLT Clinical-stage bio engages in the development of drug therapies for patients with metabolic and orphan diseases. Adult & pediatric. Insider buying recently. Gold cross on the daily. Starter today. Only 400+ watchers.
_StockTrader
Posted - 12 hours ago
Real-Time Stock Data $RZLT
Price: 3.32
Volume: 221594
Market Cap: 131217248
PE Ratio: -3.8470588
Powered by: PSYC
RallyRaider
Posted - 13 hours ago
$RZLT nice chart, the story is intact, think 4
Doorkey
Posted - 14 hours ago
$RZLT $SVRA Both are $8 June swings.
DollarDan1
Posted - 15 hours ago
$RZLT Should be interesting to see what Monday brings! Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that a poster titled "An Analysis of Overnight Hypoglycemia in Patients with Congenital Hyperinsulinism: Results from the RZ358-606 (RIZE) Study" will be presented at the Pediatric Endocrine Society (PES) Annual Meeting, to be held May 2-5, 2024 at the Sheraton Grand Chicago Riverwalk.
intratio
Posted - 20 hours ago
https://www.intratio.com/stock-forecast/RZLT Our AI estimates that the market value of this company will hedge lower in the short-term and the stock price is consistent with the company s long-term fundamentals $RZLT
Ecryder
Posted - 1 day ago
$RZLT let’s see 3.25 tomorrow
DollarDan1
Posted - 1 day ago
$RZLT Nice Pop! I guess yall's little charts got it wrong. Something is a brewin here.
ElectricJ
Posted - 1 day ago
$RZLT high higher highest...
intratio
Posted - 04/27/24
https://www.intratio.com/stock-forecast/RZLT Rezolute, Inc. Our artificial intelligence concludes the price of this stock will depreciate in the short-term and has no clear long-term directional perspective $RZLT
INTS915
Posted - 04/26/24
$RZLT , buyout is imminent @ $ 10.
_www_larval_com_
Posted - 04/25/24
$RZLT just stumbled -7% lower to -10% (~60Kv) a moment ago, follow for more volatility.
Clam_Digger
Posted - 04/25/24
$RZLT Looks like a good point to add. Presentation coming up. Get those clams 🤑🤑🤑
QKerno
Posted - 04/25/24
$RZLT
Doorkey
Posted - 04/24/24
$RZLT Just another sucky market day, it shall pass.
INTS915
Posted - 04/23/24
$RZLT , it looks like bad data presentation leaked.
INTS915
Posted - 04/23/24
$RZLT , covered @ 2.79. Shorted at 3.60. Pump n dump
intratio
Posted - 04/23/24
https://www.intratio.com/stock-forecast/RZLT The model infers that the value of this stock will hedge lower in the short-term and has no clear long-term directional perspective $RZLT
Doorkey
Posted - 04/23/24
$RZLT Free shares.
Doorkey
Posted - 04/23/24
$RZLT I think it's gonna go up, someone just got over spooked.
INTS915
Posted - 04/23/24
$RZLT , wait for $ 1.50.
Ecryder
Posted - 04/23/24
$RZLT bought in this dip
Fishbanger51
Posted - 04/23/24
$RZLT dca is the way for this one...just stealing shares prior to May conference
MoreMoneysPlease
Posted - 04/23/24
$RZLT I feel like this will rip with the slightest amount of buying pressure.
INTS915
Posted - 04/23/24
$RZLT , why dump.?????
Doorkey
Posted - 04/23/24
$RZLT 22% drop was an over reaction.
Sebastian71
Posted - 04/23/24
$RZLT whats happening ?
Clam_Digger
Posted - 04/23/24
$RZLT Time to get those clams before the presentation!!
DonCorleone77
Posted - 04/23/24
$RZLT Rezolute announces presentation of Phase 2 RIZE study sub-analyses Rezolute announced that a poster titled "An Analysis of Overnight Hypoglycemia in Patients with Congenital Hyperinsulinism: Results from the RZ358-606 Study" will be presented at the Pediatric Endocrine Society Annual Meeting, to be held May 2-5, 2024 at the Sheraton Grand Chicago Riverwalk. Paul Thorton, M.D., of Cook Children's Medical Center in Fort Worth, Texas, will present the poster, which details findings from the Company's Phase 2 RIZE study evaluating the treatment of congenital hyperinsulinism with RZ358 in pediatric patients. While primary and key secondary glycemic endpoints from the RZ358-606 study have been previously reported, the current sub-analyses highlight the benefits of RZ358 during the vulnerable overnight fasting period, utilizing continuous glucose monitor to evaluate average time in hypoglycemia and average glucose levels overnight. These and previously reported results, including improvements in overall hypoglycemia events and time of up to ~90% at the top doses, suggest that RZ358 has the potential to be a safe and effective therapy to treat all forms of congenital HI. A Phase 3 study is currently underway.